The majority of the spine market-just about 80%-is controlled by companies with annual spine revenue above $100 million. See a detailed breakdown of the top players.
Bone Therapeutics reports positive interim efficacy results and early conclusion of the Phase I/IIA study of ALLOB® allogeneic bone cell therapy in the treatment of delayed-union fractures.
Band-LOK was allowed two U.S. patents on its proprietary Tether Clamp and Implantation System, a stabilizing bone anchor for use in orthopaedic procedures.